Results 11 to 20 of about 74,894 (279)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia

Scientific Reports, 2022
Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease. However, its clinical usefulness in β-thalassaemia is unproven.
Nirmani Yasara, Nethmi Wickramarathne, Chamila Mettananda, Ishari Silva, Nizri Hameed, Kumari Attanayaka, Rexan Rodrigo, Nirmani Wickramasinghe, Lakshman Perera, Aresha Manamperi, Anuja Premawardhena, Sachith Mettananda   +11 more
doaj   +2 more sources

Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative

Frontiers in Genetics, 2022
Sickle cell disease (SCD) is an inherited blood disorder that affects about 100,000 people in the U.S., primarily Blacks/African-Americans. A multitude of complications negatively impacts quality of life. Hydroxyurea has been FDA approved since 1998 as a
Marsha J. Treadwell, Marsha J. Treadwell, Lisa Du, Neha Bhasin, Neha Bhasin, Anne M. Marsh, Theodore Wun, M. A. Bender, Trisha E. Wong, Nicole Crook, Jong H. Chung, Shannon Norman, Nicolas Camilo, Judith Cavazos, Diane Nugent   +14 more
doaj   +2 more sources

Do Genetic Polymorphisms Affect Fetal Hemoglobin (HbF) Levels in Patients With Sickle Cell Anemia Treated With Hydroxyurea? A Systematic Review and Pathway Analysis

Frontiers in Pharmacology, 2022
Hydroxyurea has long been used for the treatment of sickle cell anemia (SCA), and its clinical effectiveness is related to the induction of fetal hemoglobin (HbF), a major modifier of SCA phenotypes.
Rahyssa Rodrigues Sales, Bárbara Lisboa Nogueira, Jéssica Abdo Gonçalves Tosatti, Karina Braga Gomes, Marcelo Rizzatti Luizon, Marcelo Rizzatti Luizon   +5 more
doaj   +2 more sources

Hydroxyurea utilization among individuals with sickle cell disease in Tennessee: a pooled analysis of claims data [PDF]

Frontiers in Pharmacology
ImportanceHydroxyurea reduces severe disease among individuals living with sickle cell disease (SCD). These individuals experience high acute care utilization, but the associations between patterns of hydroxyurea utilization and healthcare utilization ...
Ayesha Mukhopadhyay, Matthew P. Smeltzer, Judy Dudley, Sherif M. Badawy, Joacy G. Mathias, Allison P. Plaxco, Meredith A. Ray, Andrew D. Wiese, Walter I. Stevens, James G. Gurney, Chinonyelum Nwosu, Jerlym S. Porter, Lisa M. Klesges, Jane S. Hankins, William O. Cooper   +14 more
doaj   +2 more sources

Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults

Health and Quality of Life Outcomes, 2017
Background Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients’ perceptions are poorly understood amongst ...
Sherif M. Badawy, Alexis A. Thompson, Jin-Shei Lai, Frank J. Penedo, Karen Rychlik, Robert I. Liem   +5 more
doaj   +2 more sources

Physiologically Based Pharmacokinetic Modelling of Hydroxyurea in Patients with Sickle Cell Disease: A Special Focus on Lactating Women and Breastfed Infants to Inform Safe Dosing and Breastfeeding Strategies [PDF]

Pharmaceuticals
Background/Objectives: Hydroxyurea is currently the standard disease-modifying therapy for reducing sickle cell disease (SCD) complications; however, drug labels currently advise discontinuation of breastfeeding during hydroxyurea therapy due to limited ...
Khaled Abduljalil, Neel Deferm, Anna Murphy, Iain Gardner   +3 more
doaj   +2 more sources

Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis

Systematic Reviews
Background Hydroxyurea is an affordable drug that reduces vaso-occlusive crises and transfusion requirements in sickle cell disease. However, its effectiveness in preventing chronic organ damage is still unclear.
Naveen Khargekar, Anindita Banerjee, Shreyasi Athalye, Namrata Mahajan, Neha Kargutkar, Prashant Tapase, Manisha Madkaikar   +6 more
doaj   +2 more sources

Beliefs about hydroxyurea in youth with sickle cell disease

Hematology/Oncology and Stem Cell Therapy, 2018
Background: Hydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients’ views of hydroxyurea is critical to optimize adherence,
Sherif M. Badawy, Alexis A. Thompson, Robert I. Liem   +2 more
doaj   +2 more sources

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

Haematologica, 2017
Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved with hydroxyurea alone or with the combination of hydroxyurea plus phlebotomies.
Alberto Alvarez-Larrán, Manuel Pérez-Encinas, Francisca Ferrer-Marín, Juan Carlos Hernández-Boluda, María José Ramírez, Joaquín Martínez-López, Elena Magro, Yasmina Cruz, María Isabel Mata, Pilar Aragües, María Laura Fox, Beatriz Cuevas, Sara Montesdeoca, José Angel Hernández-Rivas, Valentín García-Gutiérrez, María Teresa Gómez-Casares, Juan Luis Steegmann, María Antonia Durán, Montse Gómez, Ana Kerguelen, Abelardo Bárez, Mari Carmen García, Concepción Boqué, José María Raya, Clara Martínez, Manuel Albors, Francesc García, Carmen Burgaleta, Carlos Besses   +28 more
doaj   +2 more sources

Case Report: Late Hypersensitivity Reaction to Hydroxyurea in a Patient With Myeloproliferative Disorder [PDF]

Case Reports in Hematology
Hydroxyurea is a cornerstone therapy for myeloproliferative disorders such as early-stage myelofibrosis. However, rare hypersensitivity reactions can complicate its use and require careful management.
Navkirat Kahlon, Sujatha Baddam, Harinderjeet Kaur, Prabhat Singh, Zaheer Qureshi, Anusha Manje Gowda   +5 more
doaj   +2 more sources